^
    9d
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    10d
    CDAK539A12102: A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer (2025-521000-22-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539) • midazolam hydrochloride
    13d
    CDAK539A12103: A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer (2025-521001-40-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539)
    22d
    A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2029 --> Apr 2028 | Trial primary completion date: Nov 2029 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    pelabresib (DAK539)
    22d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    2ms
    Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    pelabresib (DAK539)
    3ms
    Progress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy. (PubMed, Expert Opin Investig Drugs)
    Trials assessing the efficacy of pelabresib, ABBV-744, INCB057643, BMS-986158, and OPN-2853 are detailed herein. Research into novel pan-and selective-BETis both as monotherapy and in combination with JAKis or other mechanism-based therapies are ongoing. Whether BETi therapy in MF will ultimately deliver substantial anti-clonal activity to modify disease biology and meaningfully impact clinical outcomes is yet to be determined.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABBV-744 • INCB057643 • pelabresib (DAK539) • ezobresib (BMS-986158) • zavabresib (OPN-2853)
    3ms
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    3ms
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    3ms
    A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    pelabresib (DAK539)
    4ms
    Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (clinicaltrials.gov)
    P3, N=430, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2027 --> Jun 2027
    Trial completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    10ms
    Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms. (PubMed, Curr Hematol Malig Rep)
    Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera...Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy...Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.
    Review • Journal
    |
    ASXL1 (ASXL Transcriptional Regulator 1) • IL17A (Interleukin 17A)
    |
    TP53 mutation • ASXL1 mutation
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor) • pelabresib (DAK539) • Besremi (ropeginterferon alfa-2b-njft)